Roche Holding AG RHHBF
478.19 USD -6.81 (-1.40%)
Regular-session close
485.00 Day range 485.00
375.00 52-week range 514.08
- YTD
- +7.31%
- 1 year
- +18.80%
No chart data for this range yet.
- Market cap
- 381.01B
- EPS (ttm)
- 19.32
- P/E ratio
- 24.75
- YTD return
- +7.31%
- 1-year return
- +18.80%
- Volume
- 1
- Avg volume
- 93
- Open
- 485.00
- Previous close
- 485.00
- Day's range
- 485.00 – 485.00
- 52-week range
- 375.00 – 514.08
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jul 23, 2026 | Jun 30, 2026 | 12.51 | — | — | — |
| Jan 29, 2026 | Dec 31, 2025 | 10.83 | 10.56 | -0.27 | -2.49% |
| Jul 24, 2025 | Jun 30, 2025 | 13.18 | 5.81 | -7.37 | -55.92% |
| Jan 30, 2025 | Dec 31, 2024 | 9.25 | 2.77 | -6.48 | -70.05% |
| Oct 23, 2024 | Jun 30, 2024 | 10.42 | 8.71 | -1.71 | -16.41% |
| Apr 26, 2024 | Dec 31, 2023 | 10.07 | 6.34 | -3.73 | -37.04% |
News
Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?
RHHBY Secures FDA Approval for Breast Cancer Treatment
Roche Secures First U.S. Approval for New Breast-Cancer Pill
FDA Approves Genentech's WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer
FDA approves Roche's Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer
US FDA approves Roche's oral treatment for advanced breast cancer
Roche receives FDA De Novo authorization for cobas® pro i 601 platform with Ionify® Gabapentin assay, advancing automated mass spectrometry for routine clinical laboratories
Your note
Sign in to keep a note on RHHBF — it syncs with the Stock Master app.
